The COHCCC Director has a wide array of advisory input to assist in planning for the Center's future and evaluating the outcomes of Center programs and policy implementation. The most important of these is the day-to-day decision-making body, the Cancer Center Executive Committee. This group consists of the traditional senior leaders of the Center, the Deputy Directors and Associate Directors, as well as several other key senior members of the Center. All plans either originate in or pass through this group. Our External Advisory Board continues to play a significant role in reviewing our plans and advising on our course of action. Our senior leaders. Program Leaders and Core Directors convene in the Cancer Center Leadership Council. The Core Facilities Oversight Committee reviews all Shared Resources activities and services to assure compliance and efficiency. Our Clinical Trials Minority Recruitment Committee is charged with increasing minority enrollment in clinical trials. Our ongoing full Cancer Center retreats and our individual Program retreats are key for promoting and facilitating key collaborations. Strategic planning is a dynamic process that is informally woven into the structure of each of our senior committees, both internal and external. In addition, COHCCC engages in a formal strategic planning process. Key leadership, including the Cancer Center Director and COH Chief Strategy Officer, meet to outline an appropriate process for the development of the objectives and an approach for the CCC strategy document. The approach includes data collection and analysis, multiple interviews with key CCC stakeholders, and an iterative review and approval process of the final deliverable. By design, the plan outlines specific objectives and goals and drives the future direction of the CCC while supporting its mission, vision and aspirations. Performance and progress of the stated goals within the plan are tracked and catalogued on an ongoing basis. Funding is requested for a small portion of the costs for our annual External Advisory Board meeting. Cancer Center retreat and Program retreats.
Ongoing Planning and Evaluation is essential for charting the course of the Cancer Center. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.
| Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60 |
| Chaurasiya, Shyambabu; Chen, Nanhai G; Fong, Yuman (2018) Oncolytic viruses and immunity. Curr Opin Immunol 51:83-90 |
| Liu, Stephen V; Groshen, Susan G; Kelly, Karen et al. (2018) A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 82:723-732 |
| Maestrini, Davide; Abler, Daniel; Adhikarla, Vikram et al. (2018) Aging in a Relativistic Biological Space-Time. Front Cell Dev Biol 6:55 |
| Petrossian, Karineh; Nguyen, Duc; Lo, Chiao et al. (2018) Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer. Breast Cancer Res Treat 170:499-506 |
| Murray, Jennifer; Whitson, Robert H; Itakura, Keiichi (2018) Reduced prostaglandin I2 signaling in Arid5b-/- primary skeletal muscle cells attenuates myogenesis. FASEB J 32:1868-1879 |
| Dufva, Olli; Kankainen, Matti; Kelkka, Tiina et al. (2018) Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun 9:1567 |
| Chen, Steven F; Liu, Zheng; Chaurasiya, Shyambabu et al. (2018) Identification of core aberrantly expressed microRNAs in serous ovarian carcinoma. Oncotarget 9:20451-20466 |
| Aslamy, Arianne; Oh, Eunjin; Ahn, Miwon et al. (2018) Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. J Clin Endocrinol Metab 103:1966-1976 |
| Abeywardana, Tharindumala; Oh, Myungeun; Jiang, Lei et al. (2018) CARM1 suppresses de novo serine synthesis by promoting PKM2 activity. J Biol Chem 293:15290-15303 |
Showing the most recent 10 out of 1396 publications
